[Preclinical studies for development of anti-cancer drugs: current and historical status and problems].
In this review, we present the current and historical status of preclinical studies for development of new anti-cancer drugs. In our company, especially focusing on the stage of drug screening, pharmacology, toxicology and pharmacokinetic studies. We have discovered numerous new compounds with anti-cancer potential mainly with microbial origins, from which some drugs have been developed to clinical trials. We hope that clinical trials of drugs with a new mode of action will be designed and conducted with a more rational basis, and followed by analysis of the pharmacokinetics and pharmacodynamics so as to predict the toxicity and efficacy of the drugs in humans.
Okabe
M
M
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.
Kobayashi
S
S
Hirata
T
T
Nakano
H
H
Ikegami
J
J
Inoue
K
K
Komuro
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D004285:Dogs; D004354:Drug Screening Assays, Antitumor; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats
D000970:Antineoplastic Agents